ArticleMolecular medicine (Cambridge, Mass.)2026
Evolution of Gastrointestinal Inflammatory Diseases and Neoplasm Burden in Super-Elderly Populations: Integrated GBD 2023, CHARLS, and CLHLS Analyses of China and G20 Countries.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRapid population aging has profoundly altered the epidemiological profile of gastrointestinal diseases in individuals aged ≥75 years. Although enteric infections (EI) have been effectively controlled through public health interventions, the burden of gastrointestinal inflammatory diseases (GIID) and neoplasms (GIN) continues to evolve. Systematic comparisons of temporal trends, sex differences, and age-subgroup patterns between China and G20 nations remain limited.
methodsUsing GBD 2023 data, we analyzed incident cases, age-standardized rates (ASR), and Disability-Adjusted Life Years (DALYs) of EI, GIID, and GIN among individuals aged ≥75 years in China and 19 G20 countries from 1990 to 2023. Log-linear regression was used to estimate the average annual percentage change (AAPC) in ASR, stratified by sex and 5-year age groups. Complementary individual-level analyses included an XGBoost machine-learning model with SHAP interpretability and disease co-occurrence network analysis.
resultsIn China, EI ASIR declined sharply (AAPC = -2.24%), while G20 countries showed an upward trend (AAPC = +0.65%). GIID ASIR remained essentially stable in China but rose significantly for Crohn's disease, Inflammatory Bowel Disease (IBD), and ulcerative colitis; G20 countries exhibited an overall decline. GIN shifted toward metabolism-related tumors in China (Colon and rectum cancer AAPC = +1.29%, pancreatic cancer AAPC = +0.74%), whereas esophageal and gastric cancer burdens decreased. China Health and Retirement Longitudinal Study (CHARLS) analysis identified the frailty index as the dominant predictor with clear non-linear threshold effects.Chinese Longitudinal Healthy Longevity Survey (CLHLS) networks revealed arthritis and rheumatic diseases as central hubs strongly linked to digestive disorders, highlighting chronic inflammation as the core driver of multimorbidity.
conclusionsThis study integrates GBD population trends with CHARLS and CLHLS cohort data to characterize the evolving gastrointestinal disease burden in China's super-elderly population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.